CRP has multiple high-confidence interaction partners which have been identified as potential T2DM biomarkers through network expansion (FCN2 and CFH), by Abbasi et al [16](C3) or has been suggested by experts in the RHAPSODY consortium as potential novel targets (OLR1). This evidence concerns the gene CFH and type 2 diabetes mellitus.